3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
10
Sarcoma, Alveolar Soft Part
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Interventions
Specimen Handling
2
Semaxinib
2
tin etiopurpurin
1
pembrolizumab
1
montanide ISA 51
1
cc-486
1
atezolizumab
1
Tumor Necrosis Factor-alpha
1
Tissue Banks
1
SUB1 protein, human
1
Ritonavir
1
Radiosurgery
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Mohs Surgery
1
Melphalan
1
Interleukin-2
1
Interleukin-12
1
Injections
1
Immunotherapy
1
Etoposide
1
Drug Therapy
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
Biological Therapy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
atezolizumab
×
Sarcoma
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled